Patients with hematologic malignancies who may require blood transfusions may not be able to enroll in hospice care.
ASH 2021: Focus on Sickle Cell
Advertisement
This clinical outcome translates to meaningful improvement in health-related quality of life, according to researchers.
Researchers evaluated the effects of etavopivat in two-week multiple ascending dose cohorts and a 12-week open-label study.
Researchers found no increased risk for acute deep vein thrombosis post-vaccination for approved COVID-19 vaccines.
Lead author Jacqueline N. Poston, MD, shared the findings.
The present analysis updates findings from the ongoing phase 1/2 HGB-206 study.
Researchers described the outcomes for pregnant women with SCD, who are considered at high risk for complications.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.